Is Amlodipine + Ramipril registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 4 valid registrations of Amlodipine + Ramipril, including AMLOHOPE 10 mg/10 mg Capsule (10,10 mg,mg, Capsule, hard, SAR 50.85); AMLOHOPE 10 mg/5 mg Capsule (10,5 mg,mg, Capsule, hard, SAR 45.20); AMLOHOPE 5 mg/10 mg Capsule (5,10 mg,mg, Capsule, hard, SAR 45.20); AMLOHOPE 5 mg/5 mg Capsule (5,5 mg,mg, Capsule, hard, SAR 40.25).

Active substances

Amlodipine + Ramipril

SFDA 4

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
AMLOHOPE 10 mg/10 mg Capsule	10,10 mg,mg	Capsule, hard · Oral use	30 Blister	SAR 50.85	NCE · Prescription	HEXAL AG	Valid
AMLOHOPE 10 mg/5 mg Capsule	10,5 mg,mg	Capsule, hard · Oral use	30 Blister	SAR 45.20	NCE · Prescription	HEXAL AG	Valid
AMLOHOPE 5 mg/10 mg Capsule	5,10 mg,mg	Capsule, hard · Oral use	30 Blister	SAR 45.20	NCE · Prescription	HEXAL AG	Valid
AMLOHOPE 5 mg/5 mg Capsule	5,5 mg,mg	Capsule, hard · Oral use	30 Blister	SAR 40.25	NCE · Prescription	HEXAL AG	Valid

Indications — CHI Daman Drug Formulary

HYPERTENSION

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.